We’re tracking in-house compensation. Take the Law360 Survey
Click here
February 02, 2022
Eli Lilly and Company v. Novartis Pharma AG
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
June 16, 2022
The Fourth Circuit on Thursday affirmed a Virginia district court's decision denying Eli Lilly's discovery bid related to Novartis' European patent suit over Eli Lilly's psoriasis drug Taltz, agreeing that Novartis didn't reside in the district and thus couldn't be forced to hand over evidence for use in foreign proceedings.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Get instant access to the one-stop news source for business lawyers
Register Now!
Sign up now for free access to this content